“Sarcoma” Is Not Yet a Complete Diagnosis
The term “sarcoma” does not refer to a single disease, but to a large and highly diverse group of tumours. As Dr Antonio López-Pousa explains in our video, there are dozens of different histological subtypes of sarcoma.
.png)
The term “sarcoma” does not refer to a single disease, but to a large and highly diverse group of tumours. As Dr Antonio López-Pousa explains in our video, there are dozens of different histological subtypes of sarcoma. They vary in their biological behaviour, degree of aggressiveness, prognosis and sensitivity to different types of treatment.
This is why a diagnosis of simply “sarcoma” is not enough to determine the most appropriate treatment strategy.
Today, diagnosing sarcoma involves much more than examining tissue under a microscope. In complex cases, pathologists may use immunohistochemistry and molecular diagnostic techniques such as FISH, RT-PCR or NGS. Spanish sarcoma guidelines specifically recommend molecular testing in situations where the diagnosis remains unclear, the clinical or pathological picture is unusual, or identified alterations may have implications for prognosis or treatment selection.
Why is this so important? Because an error or lack of precision at the initial diagnostic stage can affect the entire course of a patient’s treatment.
In one recent prospective study, expert review of tumour samples by a specialist sarcoma pathologist resulted in a change to the original diagnosis in approximately 31% of patients. In around 14% of cases, this also led to a change in treatment strategy. Additional molecular testing further refined the diagnosis and, in some cases, influenced subsequent treatment decisions.
These figures come from a single study and therefore cannot be applied to every patient. However, they clearly demonstrate why expert review can have genuine clinical value in rare tumours such as sarcomas.
For this reason, current Spanish recommendations advise that sarcoma cases should not be managed by a single doctor in isolation, but rather in a specialist sarcoma centre, where pathologists, oncologists, surgeons, radiologists and radiation oncologists work together as part of a multidisciplinary team.
As Dr López-Pousa explains:
“Ultimately, the entire treatment plan depends on the initial diagnosis. A good diagnosis leads to good treatment.”
Therefore, if a diagnosis has already been made but there is still uncertainty about the tumour subtype, different medical opinions have been given, or the next treatment step needs to be determined, one possible option is to have the histological material reviewed at a specialist sarcoma centre.
MedCare Iberia helps patients arrange second opinions and consultations with sarcoma specialists in Spain.